Proactive Investors - Run By Investors For Investors

CytoDyn to present data on monoclonal antibody treatment of HIV at Seattle conference

The company is completing a biologics license application with the FDA for leronlimab's use in combination therapy
A syringe
The company's once-weekly leronlimab injection is designed to block HIV-1

CytoDyn Inc (OTCMKTS:CYDY) said Wednesday that data from the study of its monoclonal antibody treatment of HIV will be presented at a Seattle conference.

The biotech company said in a statement that the data will be presented at the Conference on Retroviruses and Opportunistic Infections on March 7.

The company’s leronlimab candidate is a once-weekly injection designed to block HIV-1 from entering and infecting human cells by binding to the CCR5 receptor, a protein on the surface of white blood cells that is related to the immune system.

DEEP DIVE: CytoDyn says it’s on the cusp of a breakthrough HIV treatment after Phase 3 trial

CytoDyn’s commitment to providing groundbreaking therapeutic advances for those in need has never been stronger,” CEO Nader Pourhassan said. “We remain highly encouraged by the continued clinical and regulatory progress to bring the next generation HIV treatment to patients.”

The company is in the process of completing a biologics license application with the Food and Drug Administration for leronlimab, also known as PRO 140, as part of a combination with highly active antiretroviral therapies for HIV-infected patients.

Then, subject to the treatment's approval by the FDA as part of a combination therapy, CytoDyn plans to file for a label expansion for leronlimab as a monotherapy, providing the company can achieve positive results from a proposed Phase 3 trial.

The annual conference brings together clinical researchers from around the world to share the latest studies in the battle against HIV, AIDS and related infectious diseases. It will be held from March 4 to March 7 at the Washington State Convention Center in Seattle.

Contact Dennis Fitzgerald at [email protected]

View full CYDY profile View Profile

CytoDyn Timeline

Related Articles

patch
Sun
The New Jersey company's lead product is Twirla, a low-dose prescription contraceptive applied once weekly for three weeks, followed by a week without the patch
Oncoprex
October 17 2018
The biotech was founded by an investment group led by scientists and driven by a no-nonsense CEO whose stake is more than just business as usual
Enzymes under a microscope
April 28 2019
The Florida company applies its proprietary C1 gene expression platform to speed up the development of biologic vaccines, drugs at flexible commercial scales
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use